Tyra Biosciences expands at-the-market stock offering to $250 million

What happened

Tyra Biosciences, a pharmaceutical company focused on developing targeted therapies, filed a prospectus supplement on August 4, 2026, to expand its at-the-market (ATM) common stock offering program.

The company previously had a sales agreement with TD Cowen to sell up to $150 million of its common stock through an ATM program. As of the filing, Tyra had sold the full $150 million under that program. The amendment increases the maximum aggregate offering price to $250 million, meaning Tyra can now sell up to an additional $100 million of shares through the same mechanism.

The stock closed at $26.51 on August 4, down 1.67% from the prior close of $26.96.

What this means

An at-the-market (ATM) offering is a way for a public company to raise capital gradually by selling newly issued shares into the open market at prevailing prices, rather than through a single large underwritten offering. The company works with a sales agent (here, TD Cowen) that sells shares directly to investors on the company's behalf.

This filing is a prospectus supplement to an existing shelf registration statement (Form S-3). It updates the terms of the ATM program but does not represent a single large issuance of stock. Instead, it authorizes the company to sell shares over time as it needs capital, at prices determined by the market.

Tyra Biosciences develops cancer therapies, particularly fibroblast growth factor receptor (FGFR) inhibitors. Biotech companies often use ATM programs to fund research and development without committing to a fixed-price offering. The fact that Tyra exhausted the first $150 million and is now seeking another $100 million suggests the company is actively consuming cash for its pipeline and operations.

The stock's 1.67% decline on the day of the filing is modest and could reflect the dilutive effect of potential future share sales, though ATM sales are typically spread over weeks or months and can be less disruptive than a block trade.